Your SlideShare is downloading. ×
0
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Ipilimumab and BRAF inhibitors cutaneous toxicity
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Ipilimumab and BRAF inhibitors cutaneous toxicity

409

Published on

Some specific symptoms and signs of cutaneous toxicity for the new melanoma drugs

Some specific symptoms and signs of cutaneous toxicity for the new melanoma drugs

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
409
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. Squamous carcinoma low grade. Vemurafenib
  2. General considerations • Surgery: – At least 2 cm margin (body) – No sentinel node for lesion less 0,75- 1 mm – Lynphadenectomy: no survival benefit shown yet; prognostic value • Radiotherapy: no major indication. Abscopal effect • Drugs: adyuvant or metastatic setting
  3. Adyuvant Interferon 1 year One node with microscopic infiltration: No Interferon New drugs in the adjuvant setting in clinical trials.
  4. VITILIGO after Interferon treatment
  5. Flow sheet for metastatic melanoma Bad performance, pluripathology, clinical fragility: Paliative Care CNS metastasis and good general situation: Radiotherapy. Dabrafenib selected patients REST: + 1. BRAF mutation: --- Vemurafenib or Dabrafenib+trametinib Chemotherapy or Ipilimumab Patients with BRAF mutated melanoma, without clinical “agresivity” can start also with Ipilimumab
  6. Summary T-cell balance APC CD-28 CTLA-4 T-cell PD-1 Tumor Kill
  7. Ipilimumab dermatologi c toxicity: Pruritus, Rash, vitiligo
  8. Ipilimumab “plateau”
  9. Phase I Drug-Related Grade 2 and 3 AEs (>5% Patients) VEMURAFENIB Toxicity at 960 mg BID dose (n=32) • Toxicities were monitored and managed with dose interruption and/or modification Arthralgia 34% cuSCC 31% Rash 25% • No discontinuations for AEs Nausea 16% Fatigue 13% Photosensitivity 16% Palmar-plantar dysesthesia 13% Pruritis 13% Lymphopenia 6% 10
  10. Cutaneous SCC – Keratoacanthoma (KA) Subtype Characteristics of KA subtype • Raised button-like, central crater • Well-differentiated neoplasm with low probability of invasion/metastasis • Can grow rapidly; may involute and regress • Typically treated by excision • Observed with other agents (e.g., sorafenib) KA in the Phase I RG7204 Trial • Occurred on sun-exposed skin • Did not result in treatment discontinuation 11
  11. VEMURAFENIB cutaneous toxicity
  12. Dabrafenib toxicity Cutaneous

×